Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Journal of the National Cancer Institute

Volumn 97, Issue 2, 2005, Pages 94-102

  Lippman, Scott M ^a   Goodman, Phyllis J ^b   Klein, Eric A ^c   Parnes, Howard L ^d   Thompson Jr , Ian M ^e   Kristal, Alan R ^f   Santella, Regina M ^g   Probstfield, Jeffrey L ^h   Moinpour, Carol M ^b   Albanes, Demetrius ^d   Taylor, Philip R ^d   Minasian, Lori M ^d   Hoque, Ashraful ^a   Thomas, Sarah Moody ⁱ   Crowley, John J ^b   Gaziano, J Michael ^j   Stanford, Janet L ^f   Cook, Elise D ^a   Fleshner, Neil E ^k   Lieber, Michael M ^l   Walther, Philip J ^m   Khuri, Fadlo R ⁿ   Karp, Daniel D ^o   Schwartz, Gary G ^p   Ford, Leslie G ^d   Coltman Jr , Charles A ^q   more..

^a UNIVERSITY OF TEXAS   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g College of Physicians and Surgeons ^*  (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

^k Canadian Uro Oncology Group   (Canada)

^l North Central Cancer Treatment Group Rochester   (United States)

^m Cancer and Leukemia Group B   (United States)

ⁿ RADIATION THERAPY ONCOLOGY GROUP   (United States)

^o Eastern Cooperative Oncology Group   (United States)

^p WAKE FOREST SCHOOL OF MEDICINE   (United States)

^q Southwest Oncology Group   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; BETA CAROTENE; BETA TOCOPHEROL; BETA TOCOTRIENOL; COLECALCIFEROL; DELTA TOCOPHEROL; DELTA TOCOTRIENOL; DRUG METABOLITE; GAMMA TOCOPHEROL; GAMMA TOCOTRIENOL; INORGANIC COMPOUND; METHYLSELENOL; MULTIVITAMIN; PLACEBO; SELENITE; SELENIUM; SELENOMETHIONINE; UNCLASSIFIED DRUG; VITAMIN; ANTINEOPLASTIC AGENT;

AFRICAN AMERICAN; AGE; ARTICLE; BRAIN HEMORRHAGE; CANADA; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; COMMUNITY CARE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RETENTION; DRUG SAFETY; ETHNIC DIFFERENCE; FINANCIAL MANAGEMENT; GENOTOXICITY; HEALTH HAZARD; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; LUNG CANCER; MALE; MEDICAL DECISION MAKING; METHODOLOGY; PATIENT SELECTION; PLANNING; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PUERTO RICO; RETINITIS PIGMENTOSA; SKIN CANCER; STANDARD; STROKE; UNITED STATES; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; AGED; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

AFRICAN AMERICANS; AGED; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; CLINICAL TRIALS, PHASE III; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PATIENT SELECTION; PROSTATIC NEOPLASMS; PUERTO RICO; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SELENIUM; UNITED STATES; VITAMIN E;

EID: 13744264090     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji009     Document Type: Article

References (87)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Ries LAG, Elsner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al (eds). SEER Cancer Statistics Review, 1975-2001. Available at: http://seer.cancer.gov/csr/1975_2001/, 2004. [Last accessed: December 2, 2004.]
3. Stanford JL, Feng Z, Hamilton AS, Gilliland ED, Stephenson RA, Eley JW, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000;283:354-60.
4. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000;92:1582-92.
5. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;347:215-24.
6. Scardino PT. The prevention of prostate cancer - the delimma continues. N Engl J Med 2003;349:297-9.
7. El-Bayoumy K. The role of selenium in cancer prevention. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelpha (PA): Lippincott; 1991. p. 1-15.
8. Combs GF, Combs SB. The nutritional biochemistry of selenium. Annu Rev Nutr 1984;4:257-80.
9. Shrauzer GN. Selenomethionine: a review of its nutritional significance, metabolism and toxicity. J Nutr 2000;130:1653-6.
10. Institute of Medicine. Panel on Dietary Antioxidants and Related Compounds. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington (DC): National Academy Press, 2000.
11. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63.
12. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF Jr, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 2003;95: 1477-81.
13. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998;90:1219-24.
14. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-92.
15. Medina D, Morrison DG. Current ideas on selenium as a chemopreventive agent. Pathol Immmunopathol Res 1988;7:187-99.
16. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 1998;128:1845-54.
17. Redman C, Scott JA, Baines AT, Basye JL, Clark LC, Calley C, et al. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett 1998;125:103-10.
18. Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomark Prev 2000;9:1171-82.
19. Combs GF Jr. Considering the mechanisms of cancer prevention by selenium. Adv Exp Med Biol 2001;492:107-17.
20. Li H, Stampfer MJ, Giovannucci EL, Morris JS, Willett WC, Gaziano JM, et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 2004; 96:696-703.
21. Zhuo H, Smith AH, Steinmaus C. Selenium and lung cancer: a quantitative analysis of heterogeneity in the current epidemiological literature. Cancer Epidemiol Biomarkers Prev 2004;13:771-8
22. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004;364:1219-28.
23. Jacobs ET, Jiang R, Alberts DS, Greenberg ER, Gunter EW, Karagas MR, et al. Selenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst 2004;96:1669-75.
24. Lu J, Jiang TC, Kaeck M, Ganther H, Vadhanavikit S, Ip C, et al. Dissociation of the genotoxic and growth inhibitory effects of selenium. Biochem Pharmacol 1995;50:213-9.
25. Patterson BH, Levander OA. Naturally occurring selenium compounds in cancer chemoprevention trials: a workshop summary. Cancer Epidemiol Biomarkers Prev 1997;6:63-9.
26. Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000;60:2882-6.
27. Uden PC, Boakye HT, Kahakachchi C, Hafezi R, Nolibos P, Block E, et al. Element selective characterization of stability and reactivity of selenium species in selenized yeast. J Anal At Spectrom 2003;18:1-10.
28. Larsen EH, Hansen M, Paulin H, Moesgaard S, Reid M, Rayman M. Speciation and bioavailability of selenium in yeast-based intervention agents used in cancer chemoprevention studies. J AOAC Int 2004;87:225-32.
29. Venkateswaran V, Klotz LH, Fleshner NE. Se modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 2002;62:2540-5.
30. Wan XS, Zhou Z, Kennedy AR, Kopelovich L. In vitro evaluation of chemopreventive agents using cultured human prostate epithelial cells. Oncol Rep 2003;10:2009-14.
31. Taylor PR, Parnes HL, Lippman SM. Science peels the onion of selenium effects on prostate carcinogenesis. J Natl Cancer Inst 2004;96:645-7.
32. Waters DJ, Shen S, Cooley DM, Bostwick DG, Qian J, Combs GF Jr, et al. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst 2003;95:237-41.
33. Sabichi AL, Lee JJ, Taylor RJ, Thompson IM Jr, Miles BJ, Basler JW, et al. Selenium accumulates in prostate tissue of prostate cancer patients after short-term administration of l selenomethionine. Proc Am Assoc Cancer Res 2002;43:1007.
34. Combs GF Jr. Status of selenium in prostate cancer prevention. Br J Cancer 2004;91:195-9.
35. Pappas AM. Vitamin E: tocopherols and tocotrienols. In: Pappas AM, editor. Antioxidant status, diet, nutrition, and health. Boca Raton (FL): CRC; 1998.
36. Brigelius-Flohe R, Traber MG. Vitamin E: function and metabolism. FASEB J 1999;13:1145-55.
37. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in males smokers. N Engl J Med 1994;330:1029-35.
38. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440-6.
39. Sigounas G, Anagnostou A, Steiner M. d1-alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. Nutr Cancer 1997:28:30-5.
40. Kristal AR, Stanford JL, Cohen JH, Wicklund K, Patterson RE. Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999;8:887-92.
41. Hartman TJ, Dorgan JF, Woodson K, Virtamo J, Tangrea JA, Heinonen OP, et al. Effects of α-tocopherol supplementation on serum sex hormones in older men. Prostate 2001;46:33-8.
42. Zhang Y, Ni J, Messing EM, Chang E, Yang C-R, Yeh S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci USA 2002;99:7408-13.
43. Thompson TA, Wilding G. Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells. Mol Cancer Ther 2003;2:797-803.
44. Hartman TJ, Albanes D, Pietinen P, Hartman AM, Rautalahti M, Tangrea JA, et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev 1998;7:335-40.
45. Woodson K, Tangrea JA, Barrett MJ, Virtamo J, Taylor PR, Albanes D. Serum alpha-tocopherol and subsequent risk of lung cancer among male smokers. J Natl Cancer Inst 1999;91:1738-43.
46. Lehman J, Rao DD, Canary JJ, Judd JT. Vitamin E and relationships among tocopherols in human plasma, platelets, lymphocytes, and red blood cells. Am J Clin Nutr 1988;47:470-4.
47. Dieber-Rotheneder M, Puhl H, Waeg G, Striegl G, Esterbauer H. Effects of oral supplementation with D-alpha-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J Lipid Res 1991;32:1325-32.
48. White E, Kristal AR, Shikany JM, Wilson AC, Chen C, Mares-Perlman JA, et al. Correlates of serum alpha- and gamma-tocopherol in the Women's Health Initiative. Ann Epidemiol 2001;111:136-44.
49. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-22.
50. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36.
51. Meydani SN, Meydani M, Blumberg JB, Leka LS, Siber G, Loszewski R, et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. JAMA 1997;277:1380-6.
52. Leppala JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP. Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke 1999;30:2535-40.
53. Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel-DiFranco C, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993;111:761-72.
54. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142.
55. Israel K, Yu W, Sanders BG, Kline K. Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. Nutr Cancer 2000;36:90-100.
56. Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000;92:2018-23.
57. Ricciarelli R, Zingg JM, Azzi A. Vitamin E: protective role of a Janus molecule. FASEB J 2001;15:2314-25.
58. Traber MG, Arai H. Molecular mechanisms of vitamin E transport. Annu Rev Nutr 1999;19:343-55.
59. Freeman VL, Meydani M, Yong S, Pyle J, Wan Y, Arvizu-Durazo R, et al. Prostatic levels of tocopherols, carotenoids, and retinol in relation to plasma levels and self-reported usual dietary intake. Am J Epidemiol 2000;151:109-18.
60. Goodman GE, Schaffer S, Omenn GS, Chen C, King I. The association between lung and prostate cancer risk and serum micronutrients: results and lessons learned from CARET. Cancer Epidemiol Biomark Prev 2003;12: 518-26.
61. Weinstein SJ, Wright ME, Pietinen P, King I, Tan C, Taylor PR, Virtamo J, Albanes D. Serum α-tocopherol and γ-tocopherol in relation to prostate cancer risk in a prospective study. J Natl Cancer Inst 2005;97. In press.
62. Taylor PR, Qiao YL, Abnet CC, Dawsey SM, Yang CS, Gunter EW, et al. Prospective study of serum vitamin E levels and esophageal and gastric cancers. J Natl Cancer Inst 2003;95:1414-6.
63. Combs GF Jr, Scott ML. Nutritional interrelationships of vitamin E and selenium. BioScience 1977;27:467-73.
64. Horvath PM, Ip C. Synergistic effect of vitamin E and selenium in the chemoprevention of mammary carcinogenesis in rats. Cancer Res 1983; 43:5335-41.
65. Zu K, Ip C. Synergy between selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells. Cancer Res 2003;63:6988-95.
66. Venkateswaran V, Fleshner NE, Klotz LH. Synergistic effect of vitamin E and selenium in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 2004;7:54-6.
67. Goodman P, Lovato LC, Ryan A, Crowley J, Moinpour CM, Thompson I. Utility of the enrollment period in the Prostate Cancer Prevention Trial. Control Clin Trials 1997;18(3S):52S.
68. Bostwick DG, Qian J, Civantos F, Roehrborn CG, Montironi R. Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2004;2:228-35.
69. 3. Cancer Epidemiol Biomark Prev 1998; 7:391-5.
70. Ma JF, Nonn L, Campbell MJ, Hewison M, Feldman D, Peehl DM. Mechanisms of decreased vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Mol Cell Endocrinol 2004;221:67-74.
71. Schwartz GG, Wang M-H, Zhang M, Singh RK, Siegal GP. 1α, 25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomark Prev 1997;6:727-32.
72. Vieth R, Fraser D. Vitamin D insufficiency: no recommended dietary allowance exists for this nutrient. CMAJ 2002;166:1541-2.
73. 2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 1998;9:567-82.
74. Patterson RE, Kristal AR, Neuhouser ML. Vitamin supplements and cancer risk: epidemiologic research and recommendations. In: Bendich A, Deckelbaum RJ, editors. Primary and secondary preventive nutrition. Totowa (NJ): Humana Press; 2001.
75. John EM, Dreon DM, Koo J, Schwartz GG. Residential sunlight exposure is associated with a decreased risk of prostate cancer. J Steroid Biochem Mol Biol 2004;89:549-52.
76. Hoque A, Albanes D, Lippman SM, Spitz MR, Taylor PR, Klein EA, et al. Molecular epidemiologic studies within the selenium and vitamin E cancer prevention trial (SELECT). Cancer Causes Control 2001;12:627-33.
77. Kristal AR, King IB, Albanes D, Pollak MN, Stanzyk FZ, Santella RM, et al. Centralized blood processing for the Selenium and Vitamin E Cancer Prevention Trial (SELECT): effects of storage and shipping on carotenoids, tocopherols, IGF-I, IGFBP3, steroid hormones and lymphocyte viability. Cancer Epidemiol Biomark Prev. In press.
78. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements. Arch Neurol 2004;61:82-8.
79. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-40.
80. Meydani SN, Leka LS, Fine BC, Dallal GE, Keusch GT, Singh MF, et al. Vitamin E and respiratory tract infections in elderly nursing home residents: a randomized controlled trial. JAMA 2004;292:828-36.
81. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
82. Woodson K, Triantos S, Hartman T, Taylor PR, Virtamo J, Albanes D. Long-term alpha-tocopherol supplementation is associated with lower serum vascular endothelial growth factor levels. Anticancer Res 2002;22: 375-8.
83. Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. A randomized controlled trial. Am J Gastroenterol 2003;98:348-53.
84. Limburg P, Wei W, Ahnen D, Qiao Y, Hawk E, Wang GQ, et al. Chemoprevention of esophageal squamous cancer: randomized placebo-controlled trial in a high-risk population. Gastroenterology 2002;122:A71.
85. Hernandez LM, Wu X, Lin J, Radcliffe JD. Intake of vitamin E (2-R isomers of alpha-tocopherol) and gamma-tocopherol in a case-control study and bladder cancer risk. Proc Am Assoc Cancer Res 2004;45:904(3921).
86. Duffield-Lillico AJ, Shureiqi I, Lippman SM. Can selenium prevent colorectal cancer? A signpost from epidemiology. J Natl Cancer Inst 2004;96: 1645-7.
87. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.